【摘要】：擴張型心肌病(DCM)目前仍無特異性治療方法。DCM患者體內(nèi)抗心肌自身抗體和炎性因子失調(diào)所介導(dǎo)的心肌免疫損傷在DCM的發(fā)展中有重要作用,針對相應(yīng)免疫靶點治療(如免疫吸附、藥物阻斷抗心肌抗體作用途徑、中藥免疫調(diào)節(jié)和細胞移植等)是近年研究者探索DCM臨床免疫治療的熱點,它們將有助于實現(xiàn)在規(guī)范化心力衰竭的治療基礎(chǔ)上進一步改善DCM心臟功能和預(yù)后的目的。
[Abstract]:There is no specific treatment for dilated cardiomyopathy (DCM) at present. Myocardial immune damage mediated by anti-myocardial autoantibodies and inflammatory factor disorders in patients with DCM plays an important role in the development of DCM. In recent years, it has been a hot topic for researchers to explore the clinical immunotherapy of DCM, such as blocking the action of anti-myocardial antibody, the immunomodulation of traditional Chinese medicine and cell transplantation, etc. They will help to further improve cardiac function and prognosis of DCM on the basis of standardized heart failure therapy.
【作者單位】： 華中科技大學(xué)同濟醫(yī)學(xué)院附屬協(xié)和醫(yī)院心內(nèi)科;
【分類號】：R542.2

【參考文獻】

相關(guān)期刊論文 前2條

1 魏晶晶;袁t，

本文編號：2283165